TRX4 Therapeutic Evaluation of Different Multi-Dose Regimens in Type 1 Diabetes Mellitus (TTEDD).
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Otelixizumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Acronyms TTEDD
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 11 Oct 2017 Status changed to discontinued.
- 17 Feb 2012 Actual end date Dec 2011 added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History